Tuberc Respir Dis.  2009 Jul;67(1):1-7.

Literature Review of COPD 2008

• Lee SY

Abstract

No abstract available.

MeSH Terms

Pulmonary Disease, Chronic Obstructive

Figure

• 

  Figure 1 Proportional Venn diagram presenting the different phenotypes within the Wellington Respiratory Survey study population. The large black rectangle represents the full study group. The clear circles within each coloured area represent the proportion of subjects with COPD (post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <0.7). The isolated clear circle represents subjects with COPD who did not have an additional defined phenotype of asthma, chronic bronchitis or emphysema.

• 

  Figure 2 Schematic showing working model for DJ-1-mediated regulation of the NRF2 pathway. ARE: antioxidant response element; ROS: reactive oxygen species.

• 

  Figure 3 Fitted adjusted mortality curve evaluating the relationship between the fibronectin (F) to C-reactive protein (CRP) ratio and the hazard function for all-cause mortality. The hazard function was generated using a Cox proportional hazards model in which the relationship between the F/CRP ratio (as a continuous variable) and all-cause mortality was evaluated, adjusted for various covariates. The fitted curve is presented, with both log and natural values of F/CRP. The arrow indicates a potential threshold at a natural F/CRP value of ??50, beyond which point the hazard function does not change significantly. Hazard ratios can be calculated from this graph by determining the hazard function at a particular value of F/CRP (e.g., 2.7:_) and dividing it by the hazard function of the reference F/CRP value (e.g., 148: - - - -). In this example, the hazard ratio would be 3.

Reference

1. Snider GL. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis. 1989. 140:S3–S8.

2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007 [Internet]. c2009. [place unknown]: Global Initiative for Chronic Obstructive Lung Disease (GOLD);Available from: http://www.goldcopd.com.

3. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005. 365:1552–1560.

4. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med. 1999. 340:1948–1953.

5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000. 320:1297–1303.

6. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008. 178:332–338.

7. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007. 356:775–789.

8. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁: the lung health study. JAMA. 1994. 272:1497–1505.

9. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000. 343:1902–1909.